Updated data from the Phase 2a arm of IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer shows:

Also Read: Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Initial Data from Phase 2a Arm of IMM-1-104 with modified FOLFIRINOX in first-line pancreatic cancer:

• All evaluable patients (n=4) experienced target tumor shrinkage and disease control, with one patient achieving a 100% reduction (PR).  
• The combination of IMM-1-104 plus modified FOLFIRINOX (mFFX) was generally well tolerated.
• The company is currently evaluating the 320 mg QD dose of IMM-1-104 in combination with modified FOLFIRINOX.

Initial Data from Phase 2a of IMM-1-104 monotherapy in second-line pancreatic cancer:

• Eleven of the twenty-one evaluable patients treated with IMM-1-104 as monotherapy achieved disease control, including one patient with 67% target lesion shrinkage. Nine patients remain on treatment.
• IMM-1-104 monotherapy was well tolerated in second-line pancreatic cancer patients, suggesting that IMM-1-104 may be highly suitable for both monotherapy and combination therapy.

Immuneering also announced initial pharmacokinetic, pharmacodynamic, and safety data from the Phase 1 portion of the company’s Phase 1/2a trial of IMM-6-415.

The company says further IMM-1-104 Phase 2a data are expected in the second quarter of 2025.

Immuneering says the Phase 2a arm of IMM-1-104 in combination with BRAF inhibitor in melanoma and Phase 2a arms of IMM-1-104 in combination with checkpoint inhibitors in both melanoma and NSCLC are planned for 2025.

Price Action: IMRX stock is up 61.90% at $3.82 during the premarket session at last check Tuesday.

Read Next:

• Optimum-MSGN Standoff Could Pressure MSG Networks’ Finances: Analyst